Aramark
11 nominees · 3 ballot items.
Election of 11 director nominees; ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal 2026; advisory approval of executive compensation.
Follow how the vote landed and what changed on Aramark’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot3
- 1
Election of 11 Director Nominees
ManagementBoard: FORVote on electing the 11 director nominees listed in the proxy statement to serve until the 2027 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified.
- 2
Ratification of Deloitte & Touche LLP as Independent Registered Public Accounting Firm for 2026
ManagementBoard: FORRatify the appointment of Deloitte & Touche LLP to serve as Aramark’s independent registered public accounting firm for fiscal 2026.
- 3
Advisory Vote to Approve Executive Compensation
ManagementBoard: FORVote on a non-binding advisory basis to approve the compensation paid to Aramark’s Named Executive Officers as disclosed in the Proxy Statement.
Nominees on the ballot11
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 6.4% | 16,811,183 | $682M |
| 2 | BlackRock, Inc. | 5.2% | 13,563,874 | $550M |
| 3 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 5.1% | 13,300,343 | $539M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 11,792,640 | $478M |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.3% | 11,203,987 | $454M |
| 6 | FIDUCIARY MANAGEMENT INC /WI/ | 4.0% | 10,587,895 | $429M |
| 7 | Capital International Investors | 3.9% | 10,354,916 | $420M |
| 8 | AQR CAPITAL MANAGEMENT LLC | 3.7% | 9,837,861 | $399M |
| 9 | BlackRock, Inc. | 3.2% | 8,319,041 | $337M |
| 10 | MORGAN STANLEY | 3.1% | 8,180,314 | $332M |
Other Industrials sector meetings6
Upcoming shareholder meetings at Aramark’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Aramark 2026 annual meeting?
- Aramark (ARMK) holds its 2026 annual shareholder meeting on Tuesday, February 3, 2026.
- What is the record date for the Aramark 2026 meeting?
- The record date for the Aramark 2026 meeting is Friday, December 12, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Aramark's 2026 meeting?
- The board is presenting 11 director nominees at the Aramark 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Aramark 2026 meeting?
- Shareholders will vote on 3 proposals at the Aramark 2026 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.